
#73. The Triumph of Daraxonrasib
Episode 30
For decades, KRAS stood as oncology’s archetypal “undruggable” target—a powerful cancer driver with no obvious pocket for conventional medicines to grasp. This episode explores how molecular-glue drugs such as daraxonrasib overturn that assumption by recruiting cyclophilin A to form a synthetic complex around active RAS, physically blocking its growth signals. From the structural ingenuity behind this molecular trap to emerging clinical promise in pancreatic and other KRAS-driven cancers, the daraxonrasib FDA approval reveals a potential turning point in precision oncology—while examining resistance, patient selection, and what KRAS teaches us about drugging the seemingly impossible. Produced by Dr. Jake Chen.
Publisher
Drug Discovery AI Talk
Link
podcasters.spotify.com/pod/show/jakechen/episodes/73--The-Triumph-of-Daraxonrasib-e3oauo6
Published
September 11, 2026
Duration
19 min
Format
Podcast
Category
Issues · Tech News
Source
RSS feed
Host
Dr. Jake Chen
Drug Discovery AI Talk
@drugdiscoveryaitalk
#triumph #daraxonrasib
